Purpose: This study evaluates the radiographic appearance of lacrimal gland tissue after placement of a glaucoma drainage implant (GDI) to characterize the impact of the device on the gland's imaging patterns. Methods: We performed retrospective chart review of departmental records at two urban academic medical centers, which were systematically searched using procedure codes to identify adult glaucoma patients who underwent unilateral superotemporal GDI from January 1995 to December 2015. Radiology records were cross-checked to identify the subset of patients who underwent postoperative orbital CT or MRI. Chart review collected data on glaucoma diagnosis, management, examination findings, and clinical complaints. Imaging studies were reviewed for orbital changes using qualitative assessment of the radiographic appearances and computer-guided calculations to quantify asymmetries. Results: A review of all eye operations in the inclusion period identified 315 patients with GDI, 13 of whom were eligible for inclusion. Elapsed time from device placement to imaging averaged 41.9 months, and the average clinical follow-up was 56.4 months. Radiographic lacrimal gland changes were appreciable in 69% (9 of 13) of patients, most commonly with posterior displacement and flattening of the gland (7 of 13). ImageJ analysis revealed significantly smaller lacrimal glands in orbits with GDI (P = 0.04). No clear correlation was found between gland changes and clinical dry eye symptoms. Conclusion: GDI placement was associated with radiographically-appreciable lacrimal gland changes in two-thirds of patients, with changes occurring in a predictable pattern of lacrimal gland flattening, posteriorization, and volume loss. Radiographic changes correlated with clinical symptoms in few patients.
INTRODUCTION
Advanced glaucoma treatment has trended toward increased use of glaucoma drainage implant (GDI) devices over the past 20 years. Interval data from surveys conducted among American Glaucoma Society (AGS) members indicate that GDI usage has increased from 17.5% of all glaucoma surgery cases in 1996 to 50.8% in 2008. [1] Placement of GDI is often the treatment of choice in patients with uveitis, iris neovascularization, prior failed filtering surgery, or other complex ocular history. [1] [2] [3] The device is most commonly positioned on the superotemporal quadrant of the eye, which places it adjacent to the lacrimal gland. The radiographic appearance of the orbital soft tissues after GDI surgery has been described in case reports or small series with limited follow-up intervals; however, to our knowledge, no study has focused on the effect of the GDI on the lacrimal gland itself. [4] [5] [6] [7] [8] [9] [10] This study was conducted to evaluate the radiographic appearance of the lacrimal gland after GDI placement.
MATERIALS AND METHODS
Institutional Review Board (IRB) approval was obtained, and the work was conducted in a HIPAA-compliant manner. The clinical and surgical records of the University of Washington Medical Center and Harborview Medical Center were searched for adult patients who had undergone placement of GDI (CPT codes 66180, 66185) between January 1995 and December 2015. This search identified 315 patients, whose records were then reviewed. Patients were excluded from the study if they had bilateral GDI, non-superotemporal position of the GDI, any history of orbital trauma, prior orbital surgery or radiation, other orbital pathology, or systemic disease affecting the lacrimal gland. The remaining records were screened to determine whether a relevant imaging study (orbital CT or MRI) was performed after GDI placement, yielding a final 13 patients for inclusion.
The images were reviewed separately by a neuroradiologist and the authors with attention to the appearance of the GDI device, lacrimal gland, and neighboring orbital soft tissue. Inter-rater agreement was assessed using the Spearman's correlation coefficient (r).
Comparison was made to the contralateral side, enabling use of each patient's non-operative orbit as a control. In patients with multiple images, the images were reviewed for changes over time.
Quantitative assessment of lacrimal gland volume was performed using a validated method using ImageJ 1.47v software (Wayne Rasband, National Institutes of Health, Bethesda, MD, U.S.A.). [11] The software was downloaded from https://imagej.nih.gov/ij/. The scanned images were opened in the software; then, the lacrimal glands were manually outlined on each slice. The area of each selected region was multiplied by the slice thickness to calculate the volume [ Figure 1c ]. Outlines and calculations were repeated 3 times for each scanned image with the values averaged to improve reliability. The mean lacrimal gland volumes of the unoperated right versus left orbits were compared using a 2-sample t-test. For each patient, the gland volume on the operated side was compared to the non-operated (control) side with a paired t-test. Gland dimensions were measured tip-to-tip in axial and coronal planes as described by Tamboli et al [ Figure 1a and b]. [12] Retrospective chart review of all ophthalmology records was performed to collect data on demographic characteristics, surgical indications and dates, patient symptoms, topical medications, and clinical examination findings. Care was taken to screen for potential sources of orbital asymmetry not related to GDI, including unilateral topical prostaglandin analog usage. Special attention was paid to complaints related to tearing or dry eye in the clinical notes.
RESULTS
Thirteen patients (male, n = 7) who had undergone unilateral (right, n = 4) superotemporal GDI placement were included in the study. The mean age at surgery was 55. difference between the two sides (P = 0.124) [ Table 1 ]. A significant difference was found between orbits with GDI (0.616 cm 3 ) and control orbits (0.704 cm 3 ) with respect to lacrimal gland volume (P = 0.040). Compared to those in the control orbits, the lacrimal glands in orbits with GDIs showed flattening and posteriorization, with decreased coronal width (3.8 mm with GDI compared Elapsed time from device placement to imaging examination averaged 41.9 months (range: 3-147); there were 23 scans in total (orbital CT = 15 and orbital MRI = 8). Indications for imaging included facial pain (n = 11), orbital pain or swelling (n = 6), concern for orbital cellulitis (n = 3), unilateral vision loss (n = 2), and proptosis (n = 1). The Spearman's correlation coefficient indicated strong inter-rater reliability on recognition of lacrimal gland flattening (r = 0.91), posterior displacement (r = 0.86), fat stranding (r = 0.82), and proptosis (r = 1.0). The typical orbital imaging findings on CT and MRI are shown in Figure 2 . A side-by-side comparison of a patient before versus after GDI placement is shown in Figure 3 .
On quantitative assessment using ImageJ, the mean lacrimal gland volume in control orbits was 0.71 cm 3 on the right and 0.698 cm 3 on the left; there was no significant to 5.2 mm without; P = 0.009) and increased axial length (15.4 mm with GDI compared to 14.6 mm without; P = 0.012). There was no significant change in the lacrimal gland volume in relation to elapsed time since GDI placement (P = 0.48) when comparing subgroups of patients who were imaged 0-4 months, 5-8 months, 9-12 months, and >1 year after surgery; however, the subgroups were small (n = 2, 1, 0, and 10 patients). There was a trend toward lower gland volumes in patients with 350-mm 2 BGI compared to those with AGV or MI (P = 0.084).
Review of clinical documentation revealed that 15% (n = 2) of patients in the series noted a change in dry eye symptoms after GDI surgery. However, each patient had confounding factors, including the addition of a new glaucoma medication in one, and bilateral dry eye sensation after unilateral surgery in the other. New orbital symptoms were noted after GDI surgery in 15% (n = 2) of patients, with one patient experiencing intermittent binocular diplopia that resolved 3 months postoperatively; the other patient reported episodic superotemporal orbital pain. Although imaging and clinical examinations were unrevealing in this patient, she underwent explantation of her GDI and the symptoms resolved.
DISCUSSION
GDI placement for management of glaucoma is increasingly prevalent, with the most common position of the device being in the superotemporal orbit, near the lacrimal gland. A better understanding is needed of how this placement affects the gland, including its radiographic appearance.
Of the 3 most common GDI types, BGI devices are radiopaque on CT and plain films due to impregnation with barium, whereas MI and AGV are made up of radiolucent silicone or polypropylene. [6, 7, 10] On MRI, all 3 devices appear as a curvilinear low-intensity signal at the shunt endplate on T1-and T2-weighted images, with an associated fluid bleb that is isointense to the vitreous. In our series and others, it has been common to see the bleb fluid along both the superficial and deep face of the plate when successful filtering is occurring. [10] It is also normal to find a linear structure with soft tissue density, which likely corresponds to the Tenon's encapsulating the GDI and bleb. On CT images, the lacrimal gland tissue is hyper-dense when compared to the Tenon's capsule, which is, in turn, more radio-dense than the bleb fluid. On MRI, the gland tissue is typically isointense to the extraocular muscle, and muscle and gland both enhance with gadolinium more than the neighboring soft tissues.
Lacrimal gland dimensions and volumes in normal adults have been previously evaluated using CT and MRI modalities. In general, most studies have found no significant difference in gland dimensions between genders or between the left and right orbits; and there is a linear decrease in the gland volume with age. [12] [13] [14] [15] Although the scanned images in this study were retrospectively reviewed, which entails some limitations due to variability in patient position or image rotation, our measurements in the unoperated orbits found dimensions and volumes that are similar to the previously reported values. [12] [13] [14] [15] However, lacrimal glands in orbits with GDI were found to have significantly smaller volume, narrower coronal width, and longer axial length, suggesting that presence of the superotemporal GDI promotes flattening and shrinkage of the gland. The trend toward smaller gland volumes in orbits with larger GDIs in our series suggests the gland changes are due to mass effect; however, gland atrophy may also play a role. A prospective study to perform and evaluate orbital imaging after GDI at standard postoperative time points would be helpful to determine whether this flattening and shrinkage represents gland compression versus gland atrophy, or both.
Our study found no appreciable relationship between lacrimal gland size and dry eye related clinical complaints in patients after GDI placement. The study has several limitations that may have influenced the results, including its retrospective nature, different time lapses between surgery and imaging, small sample size, and lack of objective data on patient tear production. It is also possible that the effect of the lacrimal gland size on tearing and ocular surface disease is disguised by the larger impact of topical glaucoma therapy in this patient population. [16] A study specifically evaluating lacrimal gland volume in relation to quantitatively measured tear output, controlled for topical medications, would be of use in the future.
In conclusion, radiographically appreciable lacrimal gland changes are seen in approximately two-thirds of patients after GDI placement, but these changes can be clinically asymptomatic. Conversely, orbital symptoms ostensibly related to the GDI can occur without notable imaging abnormalities. Common changes are lacrimal gland volume loss, flattening, and posterior displacement of the gland. Developing a better understanding of these changes allows for a more meaningful interpretation of the imaging findings when patients with GDIs present with postoperative orbital complaints. Further prospective work is needed to elucidate the clinical impact of these radiographically appreciable gland changes.
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